A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma

Inclusion Criteria: * Age ≥18 and ≤70 years; * Histological diagnosis of de novo GBM (i.e. not secondary GBM); * Gross total resection as evaluated by MRI performed within 72 hours from surgery; * Karnofsky Performance Status (KPS) ≥60 at the time of first progression; * Written informed consent. Exclusion Criteria: * Pregnancy or breast feeding; * Participation in other clinical trials with experimental drugs simultaneously; * Mandatory treatment with corticosteroids or salicylates in anti-inflammatory dose; * Presence of sub-ependymal diffusion of the tumor; * Presence of multi-focal GBM lesion; * Haematology: leukocytes (WBC) \< 3x103/μl, absolute lymphocyte count\< 0.5x103/μl, Absolute neutrophil count (ANC) \< 1x103/μl, hemoglobin\< 9 g/dL, platelets\< 50x103/μl within two days prior to leukapheresis; * AST (SGOT)/ALT (SGPT) ≥3 X institutional Upper Limit Normal (ULN) at the time of leukapheresis; * Serum creatinine\>1.5 ULN or calculated creatinine clearance \< 60 ml/min at time of surgery; * Documented immune deficiency; * Documented systemic autoimmune disease; * Positivity for HBV, HIV, HCV, Treponema Pallidum; * Allergies to any component of the DC vaccine; * Other active malignancy.